Legal & General Group
BLPH

Legal & General Group’s Bellerophon Therapeutics, Inc. BLPH Stock Holding History

Legal & General Group’s Portfolio BLPH Stock Details BLPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-567
Closed -$3K – 3787
2021
Q1 		$3K Hold
567
– – ﹤0.01% 3512
2020
Q4 		$4K Hold
567
– – ﹤0.01% 3457
2020
Q3 		$6K Hold
567
– – ﹤0.01% 3374
2020
Q2 		$7K Buy
+567
New +$7.93K ﹤0.01% 3365

Other funds holding BLPH

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Legal & General Group's BLPH Position: Q2 2021 in Review

Legal & General Group sold out of Bellerophon Therapeutics, Inc. (BLPH) in Q2 2021, closing a stake of 567 shares — an estimated $3K sold.

Legal & General Group first reported a position in BLPH in Q2 2020 and held it in 4 quarters. The position peaked at $7K in Q2 2020. 27 funds tracked by Wall St. Rank hold BLPH as of Q2 2021.

  • Legal & General Group reported no remaining Bellerophon Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
  • Legal & General Group sold 567 Bellerophon Therapeutics, Inc. shares in Q2 2021, an estimated $3K.
  • Legal & General Group first reported a position in Bellerophon Therapeutics, Inc. in Q2 2020 and held it in 4 quarters.
  • Legal & General Group's Bellerophon Therapeutics, Inc. position peaked at $7K in Q2 2020.
  • 27 funds tracked by Wall St. Rank held Bellerophon Therapeutics, Inc. as of Q2 2021.

Based on Legal & General Group's 13F filing for Q2 2021, filed 12 Aug 2021.